Medtronic will add a heart failure implant and pipeline products in its $1.1 billion acquisition of HeartWare. The deal will accelerate the development of HeartWare's products and round out Medtronic's Cardiac Rhythm & Heart Failure division.
Dr. Stephen Friend, founder of Sage Bionetworks, which developed apps for Apple's ResearchKit, is moving on to work for the tech titan, effective immediately. In addition to his data experience at the open-science nonprofit, he brings 8 years of R&D experience from his time at Merck. Read more >>
A new stem cell-containing bio-ink could be used to create living tissue through 3D printing, called "bio-printing." The ink was developed by scientists at the University of Bristol, and it could eventually produce complex tissues for surgical implants. Read more >>
The FDA said it acted properly by accepting late patient injury reports from a Medtronic study that showed problems with its Infuse bone graft, adding that the information provided by the devicemaker was "consistent" with data the regulatory agency already had. Read more >>
POPULAR COMMENT THREADS
Avita Medical will gain an additional $7.96 million to support its plans for U.S. market approval and launch of ReCell. This money, from the Biomedical Advanced Research and Development Authority, supplements the $53.9 million contract that went through last September.
San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies in individual circulating tumor cells.
Stealthy MedyMatch emerged in February with plans to improve emergency room care using cognitive analysis and artificial intelligence. Now, in its first collaboration with a U.S. hospital, the company is developing its first real-time decision-support tool using data from New Jersey-based Capital Health.
Georgetown University's Institute for Reproductive Health is recruiting up to 1,200 women for a real-time study of Cycle Technologies' smartphone app that calculates a woman's fertility on a daily basis.
St. Jude Medical is expanding its cardiac resynchronization therapy portfolio with SyncAV CRT software, which just received CE mark approval. The software builds on the company's MultiPoint Pacing tech.
A pair of regional insurers has decided that treatment using Nevro's Senza neurostimulation device is experimental and will therefore not reimburse it starting next month. Nevro shares dropped 3% in response to the news Wednesday.
From Our Sister Sites
A study this week called out a majority of marketers for violating FTC native advertising rules, noting that only one-third use the proper labels.
KaloBios has pledged a fair pricing oath, but with pricing continuing to dog the entire industry, will other pharma companies consider similar moves?